Acumen Prescribed drugs, Inc. (ABOS) Q3 2025 Earnings Name November 12, 2025 8:00 AM EST
Firm Individuals
Alex Braun – VP & Head of Investor Relations
Daniel O’Connell – CEO & Director
Matt Zuga – CFO & Chief Enterprise Officer
James Doherty – President & Chief Improvement Officer
Eric Siemers – Chief Medical Officer
Convention Name Individuals
Jason Zemansky – BofA Securities, Analysis Division
Thomas Shrader – BTIG, LLC, Analysis Division
Matthew Ryan Tan – Stifel, Nicolaus & Firm, Included, Analysis Division
Presentation
Operator
Good day, and welcome to the Acumen Pharma Third Quarter 2025 Convention Name and Webcast. [Operator Instructions] As a reminder, this name could also be recorded.
I’d now like to show the decision over to Alex Braun, Head of Investor Relations. Please go forward.
Alex Braun
VP & Head of Investor Relations
Thanks, Michelle. Good morning, and welcome to the Acumen convention name to debate our enterprise replace and monetary outcomes for the quarter ended September 30, 2025. With me at present are Dan O’Connell, our Chief Government Officer; and Matt Zuga, our CFO and Chief Enterprise Officer. Matt and Dan has some temporary ready remarks, after which we’ll open the decision for questions. Becoming a member of for the Q&A session, we even have Dr. Jim Doherty, our Chief Improvement Officer; and Dr. Eric Siemers, our Chief Medical Officer.
Earlier than we start, we encourage listeners to go to the Buyers part of the Acumen web site to search out our press launch issued this morning that we’ll focus on at present. Please observe that in at present’s convention name, we could make forward-looking statements inside the which means of the federal securities legal guidelines, together with statements regarding our monetary outlook and anticipated enterprise plans. These statements are topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements.
Please see Slide 2